Real-world performance of blood-based proteomic profiling in first-line immunotherapy treatment in advanced stage non-small cell lung cancer

PURPOSE: Immune checkpoint inhibition (ICI) therapy has improved patient outcomes in advanced non-small cell lung cancer (NSCLC), but better biomarkers are needed. A clinically validated, blood-based proteomic test, or host immune classifier (HIC), was assessed for its ability to predict ICI therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Rich, Patricia, Mitchell, R Brian, Schaefer, Eric, Walker, Paul R, Dubay, John W, Boyd, Jason, Oubre, David, Page, Ray, Khalil, Mazen, Sinha, Suman, Boniol, Scott, Halawani, Hafez, Santos, Edgardo S, Brenner, Warren, Orsini, James M, Pauli, Emily, Goldberg, Jonathan, Veatch, Andrea, Haut, Mitchell, Ghabach, Bassam, Bidyasar, Savita, Quejada, Maria, Khan, Waseemullah, Huang, Kan, Traylor, Linda, Akerley, Wallace
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8552188/
https://www.ncbi.nlm.nih.gov/pubmed/34706885
http://dx.doi.org/10.1136/jitc-2021-002989

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8552188/
https://www.ncbi.nlm.nih.gov/pubmed/34706885
http://dx.doi.org/10.1136/jitc-2021-002989

Ejemplares similares